CDTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.508

-71.93%

-1.640

-1.2%

-2.140

+29.7%

Estimates Revision

The market is revising No Change the revenue expectations for Cidara Therapeutics, Inc. (CDTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 90.60%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+32.98%

In Past 3 Month

Stock Price

Go Up

+90.60%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast CDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDTX is 209.67 USD with a low forecast of 173.00 USD and a high forecast of 221.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

6 Hold

0 Sell

Hold

Current: 0.000

Low

173.00

Averages

209.67

High

221.50

Current: 0.000

Low

173.00

Averages

209.67

High

221.50

Guggenheim

Buy -> Neutral

downgrade

2025-11-17

Reason

Guggenheim

Price Target

2025-11-17

downgrade

Buy -> Neutral

Reason

Guggenheim downgraded Cidara Therapeutics (CDTX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.

BofA

Tim Anderson

Buy

maintain

$98 -> $105

2025-11-17

Reason

BofA

Tim Anderson

Price Target

$98 -> $105

2025-11-17

maintain

Buy

Reason

BofA analyst Tim Anderson raised the firm's price target on Merck (MRK) to $105 from $98 and keeps a Buy rating on the shares. The Cidara (CDTX) deal is a "reasonable" one, as the company's experimental flu drug is a novel asset with a high likelihood of technical success and complementary to Merck's Infectious Disease franchise, the analyst tells investors in a research note. The firm added that Merck shares are too cheap for the growth it should be able to deliver on a near- and long-term basis.

Morgan Stanley

Maxwell Skor

Overweight -> Equal Weight

downgrade

$221.50

2025-11-16

Reason

Morgan Stanley

Maxwell Skor

Price Target

$221.50

2025-11-16

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley analyst Maxwell Skor downgraded Cidara Therapeutics (CDTX) to Equal Weight from Overweight with a $221.50 price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.

H.C. Wainwright

Sara Nik

Buy -> Neutral

downgrade

2025-11-14

Reason

H.C. Wainwright

Sara Nik

Price Target

2025-11-14

downgrade

Buy -> Neutral

Reason

H.C. Wainwright analyst Sara Nik downgraded Cidara Therapeutics (CDTX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.

Needham

Buy

Hold

downgrade

2025-11-14

Reason

Needham

Price Target

2025-11-14

downgrade

Buy

Hold

Reason

Needham downgraded Cidara Therapeutics (CDTX) to Hold from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.

RBC Capital

Outperform -> Sector Perform

downgrade

$145

2025-11-14

Reason

RBC Capital

Price Target

$145

2025-11-14

downgrade

Outperform -> Sector Perform

Reason

RBC Capital downgraded Cidara Therapeutics (CDTX) to Sector Perform from Outperform with a price target of $221.50, up from $145, after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.

Valuation Metrics

The current forward P/E ratio for Cidara Therapeutics Inc (CDTX.O) is -27.50, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess Cidara Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.32

Current PE

-27.50

Overvalued PE

2.68

Undervalued PE

-11.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.30

Current EV/EBITDA

-27.12

Overvalued EV/EBITDA

3.49

Undervalued EV/EBITDA

-6.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

59.07

Current PS

0.00

Overvalued PS

268.79

Undervalued PS

-150.66

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CDTX News & Events

Events Timeline

No data

News

8.5

01-09Benzinga

Merck in Talks to Acquire Revolution Medicines for $28-32 Billion

7.5

01-02NASDAQ.COM

HighVista Initiates Position in Cidara with 70,904 Shares Worth $6.79 Million

7.5

01-02Fool

HighVista Strategies Acquires $6.79M Stake in Cidara Therapeutics

People Also Watch

Frequently Asked Questions

What is Cidara Therapeutics Inc (CDTX) stock price today?

The current price of CDTX is 0 USD — it has increased 0.03 % in the last trading day.

What is Cidara Therapeutics Inc (CDTX)'s business?

Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.

What is the price predicton of CDTX Stock?

What is Cidara Therapeutics Inc (CDTX)'s revenue for the last quarter?

Cidara Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Cidara Therapeutics Inc (CDTX)'s earnings per share (EPS) for the last quarter?

Cidara Therapeutics Inc. EPS for the last quarter amounts to -3.10 USD, increased 26.53 % YoY.

What changes have occurred in the market's expectations for Cidara Therapeutics Inc (CDTX)'s fundamentals?

How many employees does Cidara Therapeutics Inc (CDTX). have?

Cidara Therapeutics Inc (CDTX) has 38 emplpoyees as of January 11 2026.

What is Cidara Therapeutics Inc (CDTX) market cap?

Today CDTX has the market capitalization of 51.05M USD.